Ocumetics Technology has success in Mexico City

Executive Summary

• Ocumetics Technology Corp. completed its second surgical day in Mexico City for the first‑in‑human study of its accommodating intraocular lens, with all procedures performed safely and without complications.
• Group 1 patient surgeries are now finished; one‑month postoperative data are pending and will be released when available.
• The successful day reinforces confidence in both the safety profile of the Ocumetics lens and the surgical protocol used in the study.

Key Details

• Study Phase: First‑in‑human clinical protocol, preclinical stage, conducted in Mexico City.
• Procedure Outcome: All surgeries on Day 2 completed safely; no reported issues or complications.
• Patient Cohort: Group 1 surgeries (both Day 1 and Day 2) are now complete.
• Data Status: One‑month postoperative examinations for Group 1, Day 1 patients are still pending; results to be provided in a future update.
• Primary End Points:
• Safety – establishing baseline patient health and recovery.
• Distance vision correction – assessing ability of the Ocumetics lens to restore far vision.
• Secondary End Points:
• Product handling & surgical delivery – ensuring procedural efficiency and reliability.
• Near reading ability – evaluating restoration of close‑range vision.
• Executive Comment: Dean Burns, President & CEO, stated the company is “thrilled with the success of our second surgical day” and highlighted the momentum built in the program.

Notable Quotes

“We are thrilled with the success of our second surgical day. The momentum we are building in this program gives us great excitement as we move forward in our clinical journey.” – Dean Burns, President & CEO, Ocumetics Technology Corp.